Greater Glasgow and Clyde Medicines

Key Medicine Shortages for June 2021

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines assessed by SMC and considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary

This update covers local formulary changes and decisions not related to recent SMC advice such as formulary appeals, new drug assessments and formulary section reviews.

Management of palliative patients with Parkinson’s disease (PD) approaching end of life who are normally maintained on oral PD medicines

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines assessed by SMC and considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary

Management of Parkinson’s disease (PD) medicines in patients undergoing elective surgery who are normally maintained on oral PD medicines.

This update covers local formulary changes and decisions not related to recent SMC advice such as formulary appeals, new drug assessments and formulary section reviews

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines assessed by SMC and considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary

This update covers local formulary changes and decisions not related to recent SMC advice such as formulary appeals, new drug assessments and formulary section reviews.